` ATRC (AtriCure Inc) vs S&P 500 Comparison - Alpha Spread

ATRC
vs
S&P 500

Over the past 12 months, ATRC has outperformed S&P 500, delivering a return of +23% compared to the S&P 500's +13% growth.

Stocks Performance
ATRC vs S&P 500

Loading
ATRC
S&P 500
Add Stock

Performance Gap
ATRC vs S&P 500

Loading
ATRC
S&P 500
Difference
www.alphaspread.com

Performance By Year
ATRC vs S&P 500

Loading
ATRC
S&P 500
Add Stock

Competitors Performance
AtriCure Inc vs Peers

AtriCure Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

Nestled in the heart of the highly competitive medical device industry, AtriCure Inc. has carved a significant niche for itself by focusing on the surgical treatment of atrial fibrillation, a common and potentially serious heart rhythm disorder. Founded in 2000 and headquartered in Mason, Ohio, AtriCure designs, manufactures, and sells an array of surgical devices aimed at improving treatment outcomes for this condition. The company’s innovative technology targets the complex network of electrical signals in the heart to restore regular rhythm and mitigate the risk of stroke—a common consequence of untreated atrial fibrillation. By providing surgeons with minimally invasive tools and advanced cryoablation and radiofrequency therapy systems, AtriCure not only addresses surgical efficiency but also enhances patient recovery times, distinguishing itself from its competitors. AtriCure derives its revenue from the sale of these sophisticated products directly to hospitals and surgical centers both in the United States and internationally. Key components of its portfolio include the Synergy Ablation System, which is acclaimed for its precision in creating lesions that block erratic electrical pathways, and AtriClip, a line of devices designed to occlude the left atrial appendage, thereby reducing stroke risk. As healthcare providers increasingly recognize the benefits of surgical intervention for atrial fibrillation over alternative treatments, AtriCure's financial health is buoyed by the rising adoption of its products. The company's strategic focus on expanding its product pipeline and enhancing its global sales footprint underscores its commitment to continuous growth and innovation in cardiac care.

ATRC Intrinsic Value
23.17 USD
Overvaluation 21%
Intrinsic Value
Price
Back to Top